[{"uuid": "4300549f-4e20-498d-9d90-324941130452", "publishTime": "2021-10-12T06:39:45.000Z", "title": "India's Everest Organics starts making ingredient for Merck's COVID-19 pill", "description": "India's Everest Organics Ltd said on Tuesday it had started making the active pharmaceutical ingredient (API) for a generic version of Merck & Co's experimental antiviral drug molnupiravir to treat mild to moderate COVID-19.", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://www.reuters.com/world/india/indias-everest-organics-starts-making-molnupiravir-drug-ingredient-2021-10-12/?taid=61653e2bd5012e00018ecf7e&utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon", "imageUrls": ["https://www.reuters.com/resizer/38APhnm5Zy7CXfteAeyEafe0Jgg=/728x381/smart/filters:quality(80)/cloudfront-us-east-2.images.arcpublishing.com/reuters/QZTPPQUQMJK5HFMOIMCVLZ34NY.jpg"], "lang": "en", "cityfalconScore": 61, "additionalData": {}, "source": {"name": "reuters.com", "brandName": "Reuters", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1652606/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1652606/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1652606/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1652606/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1652606/large.png"}}, "duplicatesCount": 9, "paywall": false, "registrationRequired": false, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "ed6c3179-b19f-46b2-8c89-519160fcae6d", "publishTime": "2021-10-01T14:20:18.000Z", "title": "S&P 500 turns flat after Fitch warning; Merck boosts Dow", "description": "The S&P 500 pared early gains on Friday after Fitch warned that political wrangling over the U.S. debt limit could hurt the country's credit rating, while drugmaker Merck supported the Dow on marking progress in developing an oral COVID-19 drug.", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://www.reuters.com/business/futures-slip-ahead-inflation-factory-activity-data-2021-10-01/?taid=61572145a6777700018fe3f8&utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon", "imageUrls": ["https://www.reuters.com/resizer/TYKUetlkB_aAZ8uD4ry-6Uo81-Y=/1200x628/smart/filters:quality(80)/cloudfront-us-east-2.images.arcpublishing.com/reuters/FDBVW2JBH5OWNKDOFBDDHUTX5M.jpg"], "lang": "en", "cityfalconScore": 61, "additionalData": {}, "source": {"name": "reuters.com", "brandName": "Reuters", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1652606/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1652606/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1652606/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1652606/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1652606/large.png"}}, "duplicatesCount": 3, "paywall": false, "registrationRequired": false, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "537c626a-8db8-414b-9ac4-d4208e828fbf", "publishTime": "2021-10-01T15:36:50.000Z", "title": "Merck's $15 bln gain is stingy", "description": "Merck\u2019s potential pill for Covid-19 hit it out of the park, at least for investors. In patients with less serious illness but with risk factors like old age, it cuts hospitalizations and deaths by about 50%, the company said , sending the New Jersey-based company\u2019s market value up $15 billion Friday. That might be too stingy.", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://www.reuters.com/breakingviews/mercks-15-bln-gain-is-stingy-2021-10-01/?taid=61573d67b735d700013c6e71&utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon", "imageUrls": ["https://www.reuters.com/resizer/eWdUpPMx5s4eupgi5KVvxksSYa0=/1200x628/smart/filters:quality(80)/cloudfront-us-east-2.images.arcpublishing.com/reuters/QJCLHJISGZKHLD2VGAYMDWRDGM.jpg"], "lang": "en", "cityfalconScore": 60, "additionalData": {}, "source": {"name": "reuters.com", "brandName": "Reuters", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1652606/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1652606/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1652606/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1652606/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1652606/large.png"}}, "duplicatesCount": 3, "paywall": false, "registrationRequired": false, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "3e062298-69b4-486e-a775-388fdfcfbfed", "publishTime": "2021-10-01T11:33:41.000Z", "title": "Merck's oral Covid-19 pill is a 'profound game changer': Gottlieb", "description": "Dr. Scott Gottlieb, former FDA commissioner, joins CNBC's \"Squawk Box\" to discuss Merck's late-stage data for its oral Covid-19 pill molnupiravir.", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://www.cnbc.com/video/2021/10/01/mercks-oral-covid-19-pill-is-a-profound-game-changer-gottlieb.html?__source=twitter%7Cmain&utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon", "imageUrls": ["https://image.cnbcfm.com/api/v1/image/106950783-16330874921633087487-18985654664-1080pnbcnews.jpg?v=1633087491"], "lang": "en", "cityfalconScore": 60, "additionalData": {}, "source": {"name": "cnbc.com", "brandName": "CNBC", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1665829/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1665829/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1665829/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1665829/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1665829/large.png"}}, "duplicatesCount": 1, "paywall": false, "registrationRequired": false, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "abe3ba94-3b57-4a10-9cbd-5c0fdecc691c", "publishTime": "2021-10-05T19:30:00.000Z", "title": "What to know about Merck's COVID antiviral pill", "description": "Here's what you should know about Merck's new antiviral pill for treating COVID, and when it will be available.", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://fortune.com/2021/10/05/everything-to-know-about-mercks-covid-antiviral-pill/?utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon&xid=soc_socialflow_twitter_FORTUNE", "imageUrls": ["https://content.fortune.com/wp-content/uploads/2021/10/GettyImages-1235705320-e1633458371505.jpg?resize=1200,600"], "lang": "en", "cityfalconScore": 60, "additionalData": {}, "source": {"name": "fortune.com", "brandName": "Fortune", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/435/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/435/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/435/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/435/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/435/large.png"}}, "duplicatesCount": 0, "paywall": false, "registrationRequired": false, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "fcc11c2f-b79d-49c3-b716-3f758b607510", "publishTime": "2021-10-14T19:15:00.000Z", "title": "FDA will not make a decision on Merck's COVID antiviral pill until December", "description": "Merck is one of three antiviral drugs that treat the coronavirus.", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://fortune.com/2021/10/14/fda-will-not-make-a-decision-on-merck-covid-antiviral-pill-until-december/?utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon&xid=soc_socialflow_twitter_FORTUNE", "imageUrls": ["https://content.fortune.com/wp-content/uploads/2021/10/GettyImages-1235705320-2.jpg?resize=1200,600"], "lang": "en", "cityfalconScore": 58, "additionalData": {}, "source": {"name": "fortune.com", "brandName": "Fortune", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/435/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/435/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/435/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/435/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/435/large.png"}}, "duplicatesCount": 0, "paywall": false, "registrationRequired": false, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "8ad1cd13-e030-4656-85fc-9bf28b75e778", "publishTime": "2021-09-30T15:06:34.000Z", "title": "What to know about Merck's acquisition of Acceleron Pharma", "description": "CNBC's David Faber breaks down why Merck's $11.5 billion acquisition of Acceleron Pharma could be a risky play.", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://www.cnbc.com/video/2021/09/30/what-to-know-about-mercks-acquisition-of-acceleron-pharma.html?__source=twitter%7Cmain&utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon", "imageUrls": ["https://image.cnbcfm.com/api/v1/image/106950150-16330099801633009977-18969954100-1080pnbcnews.jpg?v=1633009980"], "lang": "en", "cityfalconScore": 57, "additionalData": {}, "source": {"name": "cnbc.com", "brandName": "CNBC", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1665829/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1665829/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1665829/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1665829/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1665829/large.png"}}, "duplicatesCount": 0, "paywall": false, "registrationRequired": false, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "6d57715c-c6b1-449f-a782-1aba68743281", "publishTime": "2021-10-01T11:35:05.000Z", "title": "Merck says its experimental COVID-19 pill reduces hospitalizations and deaths by half", "description": "If cleared, Merck's drug would be the first pill shown to treat COVID-19, a potentially major advance in efforts to fight the pandemic.", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://fortune.com/2021/10/01/merck-says-experimental-covid-19-pill-reduces-hospitalizations-deaths-half/?utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon&xid=soc_socialflow_twitter_FORTUNE", "imageUrls": ["https://content.fortune.com/wp-content/uploads/2021/10/GettyImages-1207980166.jpg?resize=1200,600"], "lang": "en", "cityfalconScore": 57, "additionalData": {}, "source": {"name": "fortune.com", "brandName": "Fortune", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/435/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/435/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/435/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/435/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/435/large.png"}}, "duplicatesCount": 0, "paywall": false, "registrationRequired": false, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "17b82b10-74b6-420c-8608-f270a08c470c", "publishTime": "2021-10-08T08:48:16.000Z", "title": "Two Indian drugmakers seek to end Merck's molnupiravir trials for moderate COVID-19", "description": "Two Indian drugmakers Aurobindo Pharma Ltd and MSN Laboratories want to discontinue their respective late-stage trials of Merck & Co's experimental antiviral drug molnupiravir in moderate COVID-19 patients.", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/aurobindo-pharma-stop-molnupiravir-trial-moderate-covid-19-patients-2021-10-08/?utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon", "imageUrls": ["https://www.reuters.com/resizer/nEFlKns0F2uuzkiS0qi6-RFx24g=/1200x628/smart/filters:quality(80)/cloudfront-us-east-2.images.arcpublishing.com/reuters/5P467FY5XFPINOXXFXAXJAJFLU.jpg"], "lang": "en", "cityfalconScore": 56, "additionalData": {}, "source": {"name": "reuters.com", "brandName": "Reuters", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1652606/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1652606/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1652606/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1652606/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1652606/large.png"}}, "duplicatesCount": 16, "paywall": false, "registrationRequired": false, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "a8ecdf9e-3af1-47d8-9ff3-90cd9443ead7", "publishTime": "2021-10-08T08:30:32.000Z", "title": "Merck's breakthrough COVID pill faces a risk: the virus could outsmart it", "description": "The likelihood that resistance will become a severe problem for the drug appears to be low, Merck says, in part because the course of treatment is short, giving the virus few chances to evolve into resistant forms.", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://fortune.com/2021/10/08/merck-molnupiravir-covid-pill-faces-risk-virus-could-outsmart-it-resistance/?utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon&xid=soc_socialflow_twitter_FORTUNE", "imageUrls": ["https://content.fortune.com/wp-content/uploads/2021/10/GettyImages-1235705320-1.jpg?resize=1200,600"], "lang": "en", "cityfalconScore": 56, "additionalData": {}, "source": {"name": "fortune.com", "brandName": "Fortune", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/435/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/435/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/435/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/435/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/435/large.png"}}, "duplicatesCount": 3, "paywall": false, "registrationRequired": false, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "efa53485-f161-4d3c-99bd-94167496acf0", "publishTime": "2021-10-11T10:53:27.000Z", "title": "Merck asks FDA to authorize its breakthrough COVID antiviral pill", "description": "An antiviral pill that people could take at home to reduce their symptoms and speed recovery could ease the crushing caseload on U.S. hospitals and help to curb outbreaks in poorer countries.", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://fortune.com/2021/10/11/merck-asks-fda-to-authorize-breakthrough-covid-antiviral-pill/?utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon&xid=soc_socialflow_twitter_FORTUNE", "imageUrls": ["https://content.fortune.com/wp-content/uploads/2021/10/GettyImages-1235705476.jpg?resize=1200,600"], "lang": "en", "cityfalconScore": 56, "additionalData": {}, "source": {"name": "fortune.com", "brandName": "Fortune", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/435/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/435/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/435/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/435/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/435/large.png"}}, "duplicatesCount": 2, "paywall": false, "registrationRequired": false, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "f9cb95c9-74ac-4d26-a621-871342c3fd37", "publishTime": "2021-10-04T05:58:08.000Z", "title": "Vaccine shares slump as Merck unveils data from its 'game-changer' COVID pill", "description": "Merck said its experimental COVID pill halves the chance of hospitalization and death.", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://fortune.com/2021/10/04/merck-covid-pill-vaccine-shares-price-fosun-moderna-biontech/?utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon&xid=soc_socialflow_twitter_FORTUNE", "imageUrls": ["https://content.fortune.com/wp-content/uploads/2021/10/GettyImages-1235416476-e1633326677887.jpeg?resize=1200,600"], "lang": "en", "cityfalconScore": 56, "additionalData": {}, "source": {"name": "fortune.com", "brandName": "Fortune", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/435/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/435/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/435/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/435/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/435/large.png"}}, "duplicatesCount": 1, "paywall": false, "registrationRequired": false, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "ff1673ea-328f-4314-94e2-241915569f1b", "publishTime": "2021-10-01T17:44:32.000Z", "title": "Merck to seek FDA authorization for antiviral Covid treatment", "description": "Merck and Ridgeback Biotherapeutics plan to seek emergency authorization for an antiviral Covid treatment. The drug is called molnupiravir and it reduces the risk of hospitalization or death from Covid by 50 percent. It showed \"compelling results\" in clinical trials, the company said.", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://www.cnbc.com/video/2021/10/01/merck-to-seek-fda-authorization-for-antiviral-covid-treatment.html?utm_campaign=cityfalcon&utm_content=Main&utm_medium=cityfalcon&utm_source=cityfalcon#Echobox=1633110649", "imageUrls": ["https://image.cnbcfm.com/api/v1/image/106951023-6ED4-QT-100121MerkCovidPill.jpg?v=1633107339"], "lang": "en", "cityfalconScore": 56, "additionalData": {}, "source": {"name": "cnbc.com", "brandName": "CNBC", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1665829/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1665829/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1665829/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1665829/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1665829/large.png"}}, "duplicatesCount": 0, "paywall": false, "registrationRequired": false, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "ab7b75ff-de38-40dd-b091-d3889c616ec0", "publishTime": "2021-09-30T18:11:16.000Z", "title": "Four firms shape Merck\u2019s $11.5 bln bet on drugmaker Acceleron", "description": "Four law firms, including Covington & Burling and Ropes & Gray, are supporting pharmaceutical giant Merck & Co\u2019s roughly $11.5 billion deal to snap up rare disease-focused drugmaker Acceleron Pharma Inc.", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://www.reuters.com/legal/litigation/four-firms-shape-mercks-115-bln-bet-drugmaker-acceleron-2021-09-30/?utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon", "imageUrls": ["https://www.reuters.com/resizer/OQUFOeCIvI10hOE3uKilfEz6yLg=/1200x628/smart/filters:quality(80)/cloudfront-us-east-2.images.arcpublishing.com/reuters/TX2NS7FOEFNERAJFTCGQ7DGI6U.jpg"], "lang": "en", "cityfalconScore": 55, "additionalData": {}, "source": {"name": "reuters.com", "brandName": "Reuters", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1652606/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1652606/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1652606/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1652606/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1652606/large.png"}}, "duplicatesCount": 3, "paywall": false, "registrationRequired": false, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "471aaf96-eeac-4cd1-ae4e-e780f948312e", "publishTime": "2021-09-22T18:50:17.000Z", "title": "Merck, Pfizer's Wyeth settle pneumococcal vaccine patent dispute", "description": "Merck Sharp & Dohme Corp and Pfizer's Wyeth LLC subsidiary have resolved a patent dispute over their competing vaccines for preventing diseases including pneumonia and meningitis, according to a Delaware court filing.", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://www.reuters.com/legal/transactional/merck-pfizers-wyeth-settle-pneumococcal-vaccine-patent-dispute-2021-09-22/?utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon", "imageUrls": ["https://www.reuters.com/resizer/AX8xsd_dqvW85LZ8PlcJTbL7I9s=/1200x628/smart/filters:quality(80)/cloudfront-us-east-2.images.arcpublishing.com/reuters/ID5CF5VGX5LEXCLOGFQBZGFWFU.jpg"], "lang": "en", "cityfalconScore": 54, "additionalData": {}, "source": {"name": "reuters.com", "brandName": "Reuters", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1652606/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1652606/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1652606/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1652606/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1652606/large.png"}}, "duplicatesCount": 3, "paywall": false, "registrationRequired": false, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "362f6430-942a-40cd-a6ce-495855e6f689", "publishTime": "2021-10-12T08:38:37.000Z", "title": "Rich countries\u2019 rush to buy Merck COVID pill risks leaving poor countries behind", "description": "A global initiative to deploy COVID therapies like Merck\u2019s molnupiravir is at risk of running into the same problems the Covax effort faced.", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://fortune.com/2021/10/12/rich-countries-rush-to-buy-merck-antiviral-pill-risks-leaving-poor-countries-behind-covid-fight/?utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon&xid=soc_socialflow_twitter_FORTUNE", "imageUrls": ["https://content.fortune.com/wp-content/uploads/2021/10/GettyImages-1230787969.jpg?resize=1200,600"], "lang": "en", "cityfalconScore": 53, "additionalData": {}, "source": {"name": "fortune.com", "brandName": "Fortune", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/435/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/435/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/435/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/435/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/435/large.png"}}, "duplicatesCount": 2, "paywall": false, "registrationRequired": false, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "c253797b-377e-452a-bdc4-1483d65a82a3", "publishTime": "2021-10-01T14:49:00.000Z", "title": "Merck\u2019s Covid-19 Drug Is a Boon for Wall Street and Main Street", "description": "The strong data for Merck\u2019s experimental Covid-19 antiviral treatment has rejuvenated the company\u2019s stock price and could jump-start the moribund biotech sector.", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://www.wsj.com/articles/mercks-covid-19-drug-is-a-boon-for-wall-street-and-main-street-11633099796?mod=rss_markets_main&utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon", "imageUrls": ["https://images.wsj.net/im-410116/social"], "lang": "en", "cityfalconScore": 51, "additionalData": {}, "source": {"name": "wsj.com", "brandName": "The Wall Street Journal", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/large.png"}}, "duplicatesCount": 4, "paywall": true, "registrationRequired": true, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "ceeeaeac-af0b-4f79-9d92-1af1b10a69e7", "publishTime": "2021-10-11T10:12:43.000Z", "title": "Merck, Ridgeback submit EUA application for their pill to treat COVID-19", "description": "Merck & Co. Inc. undefined and Ridgeback Biotherapeutics said Monday that Merck has submitted an application for Emergency Use Authorization (EUA) with the...", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://www.marketwatch.com/story/merck-ridgeback-submit-eua-application-for-their-pill-to-treat-covid-19-2021-10-11?siteid=bullytweet&utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon", "imageUrls": ["https://s.wsj.net/public/resources/MWimages/MW-GP644_MicroS_ZG_20180906154215.jpg"], "lang": "en", "cityfalconScore": 48, "additionalData": {}, "source": {"name": "marketwatch.com", "brandName": "MarketWatch", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/large.png"}}, "duplicatesCount": 3, "paywall": false, "registrationRequired": false, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "09f34e10-0175-4dce-bd83-cdfe1ab59179", "publishTime": "2021-10-04T00:00:00.000Z", "title": "Evergrande And The Debt Ceiling Could Floor Investors", "description": "Some troubles just seem to hang around and Evergrande appears to be one of them. Can Tesla and Merck fix this trouble?", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://www.forbes.com/sites/jjkinahan/2021/10/04/evergrande-and-the-debt-ceiling-could-floor-investors/?utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon", "imageUrls": ["https://thumbor.forbes.com/thumbor/fit-in/1200x0/filters%3Aformat%28jpg%29/https%3A%2F%2Fspecials-images.forbesimg.com%2Fimageserve%2F615b053ba79cc1522b79c049%2F0x0.jpg"], "lang": "en", "cityfalconScore": 48, "additionalData": {}, "source": {"name": "forbes.com", "brandName": "Forbes", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/5846/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/5846/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/5846/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/5846/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/5846/large.png"}}, "duplicatesCount": 0, "paywall": false, "registrationRequired": false, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "8e46e9a5-3ce4-43ed-9c13-8001f3b42477", "publishTime": "2021-10-13T10:40:00.000Z", "title": "This development may fully reopen the global economy \u2014 and the stock market has mostly ignored it", "description": "The Merck pill, so far, hasn't made a big dent on financial markets.", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://www.marketwatch.com/story/this-development-may-fully-reopen-the-global-economy-and-the-stock-market-has-mostly-ignored-it-11634121608?rss=1&siteid=rss&utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon", "imageUrls": ["https://images.mktw.net/im-407814/social"], "lang": "en", "cityfalconScore": 47, "additionalData": {}, "source": {"name": "marketwatch.com", "brandName": "MarketWatch", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/large.png"}}, "duplicatesCount": 8, "paywall": false, "registrationRequired": false, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "08fb7c5d-55f7-4229-a9bd-e03a348b150f", "publishTime": "2021-09-27T21:33:00.000Z", "title": "Merck Nears Deal to Acquire Acceleron Pharma", "description": "An agreement could be completed as soon as this week, giving a lift to pharmaceutical giant\u2019s work on treatments for rare diseases.", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://www.wsj.com/articles/merck-nears-deal-to-acquire-acceleron-pharma-11632778405?mod=pls_whats_news_us_business_f&utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon", "imageUrls": null, "lang": "en", "cityfalconScore": 47, "additionalData": {}, "source": {"name": "wsj.com", "brandName": "The Wall Street Journal", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/large.png"}}, "duplicatesCount": 5, "paywall": true, "registrationRequired": true, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "cf74962b-652c-42eb-8aac-dee9d9fcc7c7", "publishTime": "2021-10-12T12:02:00.000Z", "title": "Airbnb, Merck, High Tide, Square: What to Watch When the Stock Market Opens Today", "description": null, "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://www.wsj.com/articles/merck-high-tide-square-what-to-watch-when-the-stock-market-opens-today-11634035607?siteid=yhoof2&utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon&yptr=yahoo", "imageUrls": null, "lang": "en", "cityfalconScore": 47, "additionalData": {}, "source": {"name": "wsj.com", "brandName": "The Wall Street Journal", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/large.png"}}, "duplicatesCount": 4, "paywall": true, "registrationRequired": true, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "e4f8ac73-7ce0-4dab-9093-174fe799b222", "publishTime": "2021-10-01T23:26:00.000Z", "title": "Facebook, Warby Parker, Merck: Stocks That Defined the Week", "description": "Here are seven major companies whose stocks moved on the week\u2019s news.", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://www.wsj.com/articles/facebook-warby-parker-merck-stocks-that-defined-the-week-11633130801?mod=rss_markets_main&utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon", "imageUrls": null, "lang": "en", "cityfalconScore": 47, "additionalData": {}, "source": {"name": "wsj.com", "brandName": "The Wall Street Journal", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/large.png"}}, "duplicatesCount": 3, "paywall": true, "registrationRequired": true, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "4f467862-47a0-4806-9278-4c279baa644c", "publishTime": "2021-10-02T13:36:55.000Z", "title": "Coronavirus tally: Global cases of COVID-19 top 234 million and U.S. death toll passes 700,000", "description": "The global tally for the coronavirus-borne illness climbed above 234 million on Saturday, while the death toll rose above 4.79 million, according to data aggregated by Johns Hopkins University. The U.S. continues to lead the world with a total of 43.6 million cases and 700,327 deaths, after passing 700,000 overnight. The U.S. is now averaging almost 2,000 deaths a day, according to a New York Times tracker, , a slight improvement over recent trends and new cases and hospitalizations are declining. There was positive news from Merck and partner Ridgeback Biotherapeutics Friday that the the oral antiviral they developed as a treatment for COVID-19 reduced the risk of hospitalization or death in at risk adult patients with mild-to-moderate COVID by about 50% in an interim analysis of data from a Phase 3 trial. Some 7.3% of patients who received molnupiravir were either hospitalized or died through Day 29 following randomization, compared with 14.1% of patients given a placebo. The companies will submit an application for an emergency use authorization to the FDA and other regulators.", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://feeds.marketwatch.com/~r/marketwatch/marketpulse/~3/GyHyr2nj1WI/story.aspx?utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon", "imageUrls": null, "lang": "en", "cityfalconScore": 47, "additionalData": {}, "source": {"name": "marketwatch.com", "brandName": "MarketWatch", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/large.png"}}, "duplicatesCount": 2, "paywall": false, "registrationRequired": false, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "38663bb7-1977-4f93-bb6d-b7314e651006", "publishTime": "2021-10-04T12:48:52.000Z", "title": "RedHill's stock is up 7.0% as it shares new data about experimental COVID-19 drug", "description": "Shares of Redhill Biopharma Ltd. gained 7.0% in premarket trading on Monday after the company said it had new data from a Phase 2/3 clinical study evaluating its experimental oral antiviral opaganib in severely ill, hospitalized COVID-19 patients. Redhill said the treatment candidate reduced mortality by 62% when evaluating 251 of the 475 patients enrolled in the study. Several companies developing COVID-19 drugs have shared new data since Friday, when Merck & Co. Inc. said its experimental oral COVID-19 treatment helped keep people out of the hospital and from dying. The news sent Merck's shares soaring and created widespread excitement among clinicians. RedHill's stock is down 45.9% for the year, while the broader S&P 500 [S: spx] is up 14.7%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://feeds.marketwatch.com/~r/marketwatch/marketpulse/~3/hXfnqQO8ZiA/story.aspx?utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon", "imageUrls": null, "lang": "en", "cityfalconScore": 47, "additionalData": {}, "source": {"name": "marketwatch.com", "brandName": "MarketWatch", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/large.png"}}, "duplicatesCount": 2, "paywall": false, "registrationRequired": false, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "bd27a31a-9278-4358-9e97-58bcfeee7395", "publishTime": "2021-10-07T20:07:36.000Z", "title": "Why Merck\u2019s antiviral pill is not a silver bullet for COVID", "description": "Between the high cost and testing hurdles, molnupiravir may not be the \"game changer\" against COVID. Read More", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://fortune.com/2021/10/07/mercks-antiviral-pill-covid/?utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon", "imageUrls": null, "lang": "en", "cityfalconScore": 47, "additionalData": {}, "source": {"name": "fortune.com", "brandName": "Fortune", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/435/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/435/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/435/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/435/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/435/large.png"}}, "duplicatesCount": 2, "paywall": false, "registrationRequired": false, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "a9683a95-ad7f-4704-ba9b-0def797ffd6a", "publishTime": "2021-09-30T10:55:50.000Z", "title": "Merck confirms to acquire Acceleron in a deal valued at $11.5 billion", "description": "Merck & Co. said Thursday it has agreed to acquire Acceleron Pharma Inc. in a deal with an equity value of $11.5 billion that was first reported earlier this week by the Wall Street Journal. Merck will pay $180 in cash for each Acceleron share owned, in a deal that's expected to close in the fourth quarter. Accelerate is focused on treating rare diseases. \"Acceleron's innovative research has yielded an exciting late-stage candidate that complements and strengthens our growing cardiovascular portfolio and pipeline and holds the potential to build upon Merck's proud legacy in cardiovascular disease,\" Merck Chief Executive Rob Davis said in a statement. Merck shares rose 0.4% premarket, while Acceleron was up 1.9% and has gained 43% in the year to date, while the S&P 500 has gained 16%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://feeds.marketwatch.com/~r/marketwatch/marketpulse/~3/sHmYXkcttFI/story.aspx?utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon", "imageUrls": null, "lang": "en", "cityfalconScore": 47, "additionalData": {}, "source": {"name": "marketwatch.com", "brandName": "MarketWatch", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/large.png"}}, "duplicatesCount": 1, "paywall": false, "registrationRequired": false, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "2a8ff2fc-f699-41f2-8057-60808259f26f", "publishTime": "2021-10-01T14:49:00.000Z", "title": "Merck's Covid-19 Drug Is a Boon for Wall Street", "description": "The strong data for Merck\u2019s experimental Covid-19 antiviral treatment has rejuvenated the company\u2019s stock price and could jump-start the moribund biotech sector.", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://www.wsj.com/articles/mercks-covid-19-drug-is-a-boon-for-wall-street-and-main-street-11633099796?mod=rss_markets_main&utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon", "imageUrls": null, "lang": "en", "cityfalconScore": 47, "additionalData": {}, "source": {"name": "wsj.com", "brandName": "The Wall Street Journal", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/large.png"}}, "duplicatesCount": 1, "paywall": true, "registrationRequired": true, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "09a7fc97-190b-4699-9bd0-f93f2711bf50", "publishTime": "2021-10-11T10:01:00.000Z", "title": ": Merck, Ridgeback submit EUA application to FDA for COVID-19 pill", "description": "This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news.", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://feeds.marketwatch.com/~r/marketwatch/realtimeheadlines/~3/vjQIakt8nao/quotes.asp?utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon", "imageUrls": null, "lang": "en", "cityfalconScore": 47, "additionalData": {}, "source": {"name": "marketwatch.com", "brandName": "MarketWatch", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/large.png"}}, "duplicatesCount": 1, "paywall": false, "registrationRequired": false, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "48a932e5-9454-46f2-b167-f816c7f7dfcf", "publishTime": "2021-10-01T10:34:26.000Z", "title": "Coronavirus tally: Global cases of COVID-19 top 223.7 million and Merck says antiviral is effective as treatment", "description": "The global tally for the coronavirus-borne illness climbed above 233.7 million on Friday, while the death toll rose above 4.78 million, according to data aggregated by Johns Hopkins University. The U.S. continues to lead the world with a total of 43.4 million cases and 697,849 deaths. The U.S. is now averaging almost 2,000 deaths a day, according to a New York Times tracker, , although new cases and hospitalizations are declining. There was positive news from Merck and partner Ridgeback Biotherapeutics that the the oral antiviral they developed as a treatment for COVID-19 reduced the risk of hospitalization or death in at risk adult patients with mild-to-moderate COVID by about 50% in an interim analysis of data from a Phase 3 trial. Some 7.3% of patients who received molnupiravir were either hospitalized or died through Day 29 following randomization, compared with 14.1% of patients given a placebo. The companies will submit an application for an emergency use authorization to the FDA and other regulators.", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://feeds.marketwatch.com/~r/marketwatch/marketpulse/~3/bAQqnDTOsYc/story.aspx?utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon", "imageUrls": null, "lang": "en", "cityfalconScore": 47, "additionalData": {}, "source": {"name": "marketwatch.com", "brandName": "MarketWatch", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/large.png"}}, "duplicatesCount": 0, "paywall": false, "registrationRequired": false, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "62ef2a5c-3fa1-4c87-9b71-fb1c4822af1c", "publishTime": "2021-10-01T10:00:00.000Z", "title": "Pill Intended to Be Covid-19's Tamiflu Succeeds in Key Study", "description": "The drug from Merck and Ridgeback Biotherapeutics cut the risk of hospitalization or death among subjects by 50% in an early look at the study\u2019s progress.", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://www.wsj.com/articles/pill-intended-to-be-covid-19s-tamiflu-succeeds-in-key-study-11633082401?mod=pls_whats_news_us_business_f&utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon", "imageUrls": null, "lang": "en", "cityfalconScore": 47, "additionalData": {}, "source": {"name": "wsj.com", "brandName": "The Wall Street Journal", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/large.png"}}, "duplicatesCount": 0, "paywall": true, "registrationRequired": true, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "7037fcf0-621a-412c-9083-ae94fdbed54e", "publishTime": "2021-10-10T21:48:00.000Z", "title": "Who Slowed Merck's Covid Remedy?", "description": "A \u2018whistleblower,\u2019 not Trump officials, delayed funding for molnupiravir.", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://www.wsj.com/articles/covid-remedy-antiviral-government-funding-merck-molnupiravir-11633897174?utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon", "imageUrls": null, "lang": "en", "cityfalconScore": 47, "additionalData": {}, "source": {"name": "wsj.com", "brandName": "The Wall Street Journal", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/large.png"}}, "duplicatesCount": 0, "paywall": true, "registrationRequired": true, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "e465a59a-2699-4d5a-ac0e-4a87e7611a71", "publishTime": "2021-10-15T11:42:39.000Z", "title": "FDA to hold advisory committee for Merck's experimental COVID-19 pill", "description": "Shares of Merck & Co. Inc. were down 0.1% in premarket trading on Friday, the day after the Food and Drug Administration said it plans to convene an advisory committee on Nov. 30 to discuss the company's experimental COVID-19 pill, molnupiravir. Merck is developing the antiviral with the privately held Ridgeback Biotherapeutics; it recently applied for emergency authorization. The FDA requested advisory committee meetings for each of the authorized COVID-19 vaccines but it did not convene one ahead of the authorizations of the monoclonal antibodies or Gilead Sciences Inc.'s remdesivir, an antiviral used to treat severely ill COVID-19 patients that is now fully approved. \"We believe that, in this instance, a public discussion of these data with the agency's advisory committee will help ensure clear understanding of the scientific data and information that the FDA is evaluating to make a decision about whether to authorize this treatment for emergency use,\" Dr. Patrizia Cavazzoni, director of the FDA's Center for Drug Evaluation and Research, said in a statement.", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://feeds.marketwatch.com/~r/marketwatch/marketpulse/~3/YMYnScGQfw0/story.aspx?utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon", "imageUrls": null, "lang": "en", "cityfalconScore": 47, "additionalData": {}, "source": {"name": "marketwatch.com", "brandName": "MarketWatch", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/large.png"}}, "duplicatesCount": 0, "paywall": false, "registrationRequired": false, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "b0e9ee1c-065e-4e2d-93c2-ae14e31a1522", "publishTime": "2021-09-30T17:58:00.000Z", "title": "Merck\u2019s Buy of Acceleron Will Help Prepare for Keytruda Patent Cliff, CEO Says", "description": "Merck CEO Robert Davis sees \"a multibillion-dollar opportunity\" with the acquisition of Acceleron. Merck's Keytruda will lose patent exclusivity in seven years.", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://www.marketwatch.com/articles/merck-stock-acceleron-51633024595?utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon", "imageUrls": ["https://images.barrons.com/im-409318/social"], "lang": "en", "cityfalconScore": 46, "additionalData": {}, "source": {"name": "marketwatch.com", "brandName": "MarketWatch", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/large.png"}}, "duplicatesCount": 0, "paywall": false, "registrationRequired": false, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "9f6e8cef-20c8-4387-b7f7-a812e56cd615", "publishTime": "2021-10-14T17:17:00.000Z", "title": "The success of Merck's antiviral\u2014and other COVID-19 pills in development\u2014may depend on how quickly people start taking them", "description": "Researchers are hopeful that these pills may also be able to reduce how long someone is infectious or sick\u2014or even prevent people from ending up with long...", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://www.marketwatch.com/story/the-success-of-mercks-antiviraland-other-covid-19-pills-in-developmentmay-depend-on-how-quickly-people-start-taking-them-11634231843?siteid=bullytweet&utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon", "imageUrls": ["https://images.mktw.net/im-416789/social"], "lang": "en", "cityfalconScore": 44, "additionalData": {}, "source": {"name": "marketwatch.com", "brandName": "MarketWatch", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/large.png"}}, "duplicatesCount": 3, "paywall": false, "registrationRequired": false, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "4aad8814-ff34-4d9d-9db2-8053dbead4e1", "publishTime": "2021-09-28T15:03:00.000Z", "title": "Only 47 stocks in the S&P 500 have fallen over the past year \u2014 Wall Street predicts they will climb up to 54% in 12 months", "description": "Activision, FedEx and Merck are on this stock-market list.", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://www.marketwatch.com/story/only-47-stocks-in-the-s-p-500-have-fallen-over-the-past-year-wall-street-predicts-they-will-climb-up-to-54-in-12-months-11632841404?utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon", "imageUrls": ["https://images.mktw.net/im-407890/social"], "lang": "en", "cityfalconScore": 43, "additionalData": {}, "source": {"name": "marketwatch.com", "brandName": "MarketWatch", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/large.png"}}, "duplicatesCount": 8, "paywall": false, "registrationRequired": false, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "47816ec9-b9ec-4562-b857-be446164c58a", "publishTime": "2021-10-13T13:10:00.000Z", "title": "Merck\u2019s Covid-19 Antiviral Can Still Get FDA Authorization, Despite Safety Concerns, Analyst Says", "description": "Citi Research looks into safety concerns about Merck's antiviral molnupiravir, and says the drug should still get approved by the Food and Drug Administration.", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://www.marketwatch.com/articles/merck-stock-covid-19-antiviral-fda-51634130494?utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon", "imageUrls": ["https://images.barrons.com/im-416189/social"], "lang": "en", "cityfalconScore": 42, "additionalData": {}, "source": {"name": "marketwatch.com", "brandName": "MarketWatch", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/large.png"}}, "duplicatesCount": 0, "paywall": false, "registrationRequired": false, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "16510f6c-1030-4821-9424-1a4a8daa2c2f", "publishTime": "2021-10-12T00:48:16.000Z", "title": "Dr. Scott Gottlieb says Merck's Covid pill \u2018can make a real difference\u2019", "description": "Dr. Scott Gottlieb explains why he thinks the Merck Covid pill \u2018can make a real difference.\u2019", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://www.cnbc.com/2021/10/11/dr-scott-gottlieb-says-mercks-covid-pill-can-make-a-real-difference.html?utm_campaign=cityfalcon&utm_content=Main&utm_medium=cityfalcon&utm_source=cityfalcon&utm_term=Autofeed#Echobox=1633999893", "imageUrls": ["https://image.cnbcfm.com/api/v1/image/106942294-16317257132021-09-15t170412z_1854910469_rc2fqp9skqyi_rtrmadp_0_usa-funds-salt.jpeg?v=1631725780"], "lang": "en", "cityfalconScore": 41, "additionalData": {}, "source": {"name": "cnbc.com", "brandName": "CNBC", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1665829/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1665829/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1665829/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1665829/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1665829/large.png"}}, "duplicatesCount": 8, "paywall": false, "registrationRequired": false, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "88a4fa4a-b418-4dfa-b09b-b9d3558717aa", "publishTime": "2021-10-01T16:50:00.000Z", "title": "Why a pill you take at home could change the direction of the pandemic", "description": "Merck and Ridgeback Therapeutics Inc.'s promising oral antiviral could shift the direction of the pandemic by making it easier for people with COVID-19 to...", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://www.marketwatch.com/story/why-a-pill-you-take-at-home-could-change-the-direction-of-the-pandemic-11633107022?utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon", "imageUrls": ["https://images.mktw.net/im-410070/social"], "lang": "en", "cityfalconScore": 41, "additionalData": {}, "source": {"name": "marketwatch.com", "brandName": "MarketWatch", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/large.png"}}, "duplicatesCount": 2, "paywall": false, "registrationRequired": false, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "9ae1750c-88a8-4b28-996a-83aead8b1629", "publishTime": "2021-10-01T16:53:00.000Z", "title": "Moderna and Novavax Stocks Are Tumbling Because Good News on a Covid Pill Is Bad News for Vaccines", "description": "Vaccine manufacturer stocks slumped Friday after Merck announced promising results for a Covid-19 oral pill.", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://www.marketwatch.com/articles/moderna-stock-novavax-covid-vaccine-51633107009?mod=mw_latestnews&utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon", "imageUrls": ["https://images.barrons.com/im-410080/social"], "lang": "en", "cityfalconScore": 40, "additionalData": {}, "source": {"name": "marketwatch.com", "brandName": "MarketWatch", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/large.png"}}, "duplicatesCount": 10, "paywall": false, "registrationRequired": false, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "9a7c585b-564a-4796-b112-1c1ec15780f2", "publishTime": "2021-10-01T14:29:06.000Z", "title": "'It is a game changer' \u2014 Cramer says Merck's new Covid pill could send stock even higher", "description": "\"This is the game changer we've been looking for,\" CNBC's Jim Cramer said Friday, adding it could make people less scared about getting Covid at work.", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://www.cnbc.com/2021/10/01/cramer-says-mercks-new-covid-pill-could-send-stock-even-higher.html?utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon", "imageUrls": ["https://image.cnbcfm.com/api/v1/image/106349607-1579721279110img_3326r.jpg?v=1579721358"], "lang": "en", "cityfalconScore": 40, "additionalData": {}, "source": {"name": "cnbc.com", "brandName": "CNBC", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1665829/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1665829/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1665829/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1665829/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1665829/large.png"}}, "duplicatesCount": 8, "paywall": false, "registrationRequired": false, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "08667258-58fc-416d-9b21-c30f55324c3c", "publishTime": "2021-10-15T15:04:00.000Z", "title": "Don\u2019t Count Out Covid-19 Monoclonal Antibody Treatments, Analyst Says. These Are the Stocks to Watch.", "description": "Trial results from Merck\u2019s oral Covid-19 antiviral dented the stocks of other biopharma firms that sell monoclonal antibody treatments for the disease,...", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://www.marketwatch.com/articles/regeneron-vir-stock-covid-19-antibody-51634310122?mod=mw_latestnews&utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon", "imageUrls": ["https://images.barrons.com/im-417840/social"], "lang": "en", "cityfalconScore": 40, "additionalData": {}, "source": {"name": "marketwatch.com", "brandName": "MarketWatch", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/large.png"}}, "duplicatesCount": 0, "paywall": false, "registrationRequired": false, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "6330c06b-226d-455a-ad81-3312371c8400", "publishTime": "2021-10-08T08:37:23.000Z", "title": "Merck drug less effective against moderate COVID -India regulatory source", "description": "Merck & Co's experimental antiviral drug molnupiravir has not shown \"significant efficacy\" against moderate COVID-19, a source with the Drug Controller General of India said.", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/merck-drug-less-effective-against-moderate-covid-india-regulatory-source-2021-10-08/?utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon", "imageUrls": ["https://www.reuters.com/resizer/wCzb5VOmbqPioM-P80o69mBoeL8=/1200x628/smart/filters:quality(80)/cloudfront-us-east-2.images.arcpublishing.com/reuters/ZBQZHJ7YZBNOFETMA2FECRN3VU.jpg"], "lang": "en", "cityfalconScore": 39, "additionalData": {}, "source": {"name": "reuters.com", "brandName": "Reuters", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1652606/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1652606/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1652606/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1652606/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1652606/large.png"}}, "duplicatesCount": 14, "paywall": false, "registrationRequired": false, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "a147c995-dc5c-4b37-a0b1-43de3d57ca07", "publishTime": "2021-10-11T10:00:00.000Z", "title": "Merck Asks FDA to Authorize Promising Covid-19 Pill", "description": "The drug could fill a big need for a pill that patients could easily take at home to help avoid hospitalization.", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://www.wsj.com/articles/merck-asks-fda-to-authorize-promising-covid-19-pill-11633946402?mod=e2tw&utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon", "imageUrls": ["https://images.wsj.net/im-414753/social"], "lang": "en", "cityfalconScore": 39, "additionalData": {}, "source": {"name": "wsj.com", "brandName": "The Wall Street Journal", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/large.png"}}, "duplicatesCount": 3, "paywall": true, "registrationRequired": true, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "8237b8aa-fceb-4adb-96f5-59984e0637c4", "publishTime": "2021-10-12T10:46:00.000Z", "title": "Merck, High Tide, Square: What to Watch When the Stock Market Opens Today", "description": "Merck shares were ticking higher premarket; Cannabis company High Tide\u2019s stock jumped on an approval to operate in British Columbia", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://www.wsj.com/articles/merck-high-tide-square-what-to-watch-when-the-stock-market-opens-today-11634035607?reflink=e2twmkts&utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon", "imageUrls": ["https://images.wsj.net/im-412261/social"], "lang": "en", "cityfalconScore": 38, "additionalData": {}, "source": {"name": "wsj.com", "brandName": "The Wall Street Journal", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/large.png"}}, "duplicatesCount": 13, "paywall": true, "registrationRequired": true, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "5e2dc872-acfe-4252-a1ff-9d3766c61c2e", "publishTime": "2021-10-01T00:00:00.000Z", "title": "Dow Rallies Nearly 500 Points After Merck\u2019s Covid Pill \u2018Injects Life\u2019 Into Slumping Stocks", "description": "The pharmaceutical giant soared 10% on Friday, helping the Dow reverse massive losses from its down week.", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://www.forbes.com/sites/jonathanponciano/2021/10/01/dow-rallies-nearly-500-points-after-mercks-covid-pill-injects-life-into-slumping-stocks/?utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon&utm_term=Gordie", "imageUrls": ["https://thumbor.forbes.com/thumbor/fit-in/1200x0/filters%3Aformat%28jpg%29/https%3A%2F%2Fspecials-images.forbesimg.com%2Fimageserve%2F609d3c45f9e26d246e5349ce%2F0x0.jpg%3FcropX1%3D351%26cropX2%3D5497%26cropY1%3D1003%26cropY2%3D3898"], "lang": "en", "cityfalconScore": 38, "additionalData": {}, "source": {"name": "forbes.com", "brandName": "Forbes", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/5846/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/5846/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/5846/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/5846/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/5846/large.png"}}, "duplicatesCount": 4, "paywall": false, "registrationRequired": false, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "1214002e-170e-4648-9343-bacdf6a394bb", "publishTime": "2021-10-01T10:16:27.000Z", "title": "Merck shares jump 3.5% premarket after it reveals positive data in trial of COVID-19 antiviral", "description": "Merck shares undefined jumped 3.5% in premarket trade Friday, after the company said the oral antiviral it developed as a treatment for COVID-19 with partner...", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://www.marketwatch.com/story/merck-shares-jump-35-premarket-after-it-reveals-positive-data-in-trial-of-covid-19-antiviral-2021-10-01?siteid=bullytweet&utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon", "imageUrls": ["https://s.wsj.net/public/resources/MWimages/MW-GP644_MicroS_ZG_20180906154215.jpg"], "lang": "en", "cityfalconScore": 38, "additionalData": {}, "source": {"name": "marketwatch.com", "brandName": "MarketWatch", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/large.png"}}, "duplicatesCount": 3, "paywall": false, "registrationRequired": false, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "bc5ec200-b0f3-42da-b019-d289d54422b0", "publishTime": "2021-10-11T10:49:00.000Z", "title": "Merck Submits Its Covid-19 Pill for Emergency FDA Approval. The Stock Slips.", "description": "Molnupiravir, an oral antiviral, is shown in a late-stage trial to reduce the risk of hospitalization or death by around 50%.", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://www.marketwatch.com/articles/merck-mrk-covid-19-pill-emergency-fda-approval-51633949366?utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon", "imageUrls": ["https://images.barrons.com/im-253790/social"], "lang": "en", "cityfalconScore": 38, "additionalData": {}, "source": {"name": "marketwatch.com", "brandName": "MarketWatch", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/large.png"}}, "duplicatesCount": 0, "paywall": false, "registrationRequired": false, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "2a875a7d-7237-4163-89d8-85a90c99f280", "publishTime": "2021-10-11T10:47:00.000Z", "title": "Marathon Digital, Occidental, Southwest, Merck: What to Watch When the Stock Market Opens Today", "description": "Bond markets are closed for a federal holiday, but the stock market is open for business.", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://www.wsj.com/articles/marathon-digital-occidental-southwest-merck-what-to-watch-when-the-stock-market-opens-today-11633949267?reflink=e2twmkts&utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon", "imageUrls": ["https://images.wsj.net/im-385606/social"], "lang": "en", "cityfalconScore": 36, "additionalData": {}, "source": {"name": "wsj.com", "brandName": "The Wall Street Journal", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/large.png"}}, "duplicatesCount": 19, "paywall": true, "registrationRequired": true, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "71fc56e6-9455-4ff8-91f9-0ea90822191f", "publishTime": "2021-10-01T00:00:00.000Z", "title": "Moderna Crash Wipes Out $22 Billion In Value After Merck\u2019s Covid Pill Triggers Vaccine Stock Plunge", "description": "Moderna tanked 15% Friday, while Novavax and BioNtech sank as much as 18%.", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://www.forbes.com/sites/jonathanponciano/2021/10/01/moderna-crash-wipes-out-22-billion-in-value-after-mercks-covid-pill-triggers-vaccine-stock-plunge/?sh=3146b9545f67&utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon", "imageUrls": ["https://thumbor.forbes.com/thumbor/fit-in/1200x0/filters%3Aformat%28jpg%29/https%3A%2F%2Fspecials-images.forbesimg.com%2Fimageserve%2F5fb28ca3d78ca241bff521b6%2F0x0.jpg"], "lang": "en", "cityfalconScore": 36, "additionalData": {}, "source": {"name": "forbes.com", "brandName": "Forbes", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/5846/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/5846/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/5846/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/5846/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/5846/large.png"}}, "duplicatesCount": 1, "paywall": false, "registrationRequired": false, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "cc4c0b18-6833-4be3-bb4b-3b79343dc904", "publishTime": "2021-10-01T00:00:00.000Z", "title": "Merck Says Its Antiviral Pill Cuts Risk Of Covid Hospitalizations, Deaths By Half", "description": "Merck said it would seek emergency approval for the first antiviral pill to treat Covid-19 off the back of the study.", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://www.forbes.com/sites/roberthart/2021/10/01/merck-says-its-antiviral-pill-cuts-risk-of-covid-hospitalizations-deaths-by-half/?utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon&utm_term=Gordie", "imageUrls": ["https://thumbor.forbes.com/thumbor/fit-in/1200x0/filters%3Aformat%28jpg%29/https%3A%2F%2Fspecials-images.forbesimg.com%2Fimageserve%2F6156ea2242ae2486c9fe0d71%2F0x0.jpg%3FcropX1%3D0%26cropX2%3D3254%26cropY1%3D126%26cropY2%3D1957"], "lang": "en", "cityfalconScore": 36, "additionalData": {}, "source": {"name": "forbes.com", "brandName": "Forbes", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/5846/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/5846/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/5846/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/5846/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/5846/large.png"}}, "duplicatesCount": 0, "paywall": false, "registrationRequired": false, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "79be9c9c-9157-4bc6-a053-d816f3ff1692", "publishTime": "2021-10-01T10:01:27.000Z", "title": "Merck says oral Covid treatment reduces risk of hospitalization, death by half for some patients", "description": "Merck and Ridgeback Biotherapeutics will seek emergency authorization for their drug, which they say could have \u201ca profound impact in controlling the pandemic.\u201d", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://www.cnbc.com/2021/10/01/merck-to-seek-emergency-authorization-for-oral-covid-19-treatment.html?__source=newsletter%7Cbreakingnews&utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon", "imageUrls": ["https://image.cnbcfm.com/api/v1/image/106937267-1630675401978-gettyimages-1235024685-AFP_9M64U6.jpeg?v=1630675464"], "lang": "en", "cityfalconScore": 36, "additionalData": {}, "source": {"name": "cnbc.com", "brandName": "CNBC", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1665829/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1665829/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1665829/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1665829/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1665829/large.png"}}, "duplicatesCount": 0, "paywall": false, "registrationRequired": false, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "9f80f322-0b5e-4949-a2b3-c2631e3738a7", "publishTime": "2021-10-01T10:00:00.000Z", "title": "Pill Intended to Be Covid-19\u2019s Tamiflu Succeeds in Key Study", "description": "The drug from Merck and Ridgeback Biotherapeutics cut the risk of hospitalization or death among subjects by 50% in an early look at the study\u2019s progress.", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://www.wsj.com/articles/pill-intended-to-be-covid-19s-tamiflu-succeeds-in-key-study-11633082401?mod=e2tw&utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon", "imageUrls": ["https://images.wsj.net/im-409950/social"], "lang": "en", "cityfalconScore": 35, "additionalData": {}, "source": {"name": "wsj.com", "brandName": "The Wall Street Journal", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/large.png"}}, "duplicatesCount": 13, "paywall": true, "registrationRequired": true, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "000a55db-259b-4355-b780-437214d9c8c0", "publishTime": "2021-09-27T21:33:00.000Z", "title": "WSJ News Exclusive | Merck Nears Deal to Acquire Acceleron Pharma", "description": "An agreement could be completed as soon as this week, giving a lift to pharmaceutical giant\u2019s work on treatments for rare diseases.", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://www.wsj.com/articles/merck-nears-deal-to-acquire-acceleron-pharma-11632778405?mod=latest_headlines&utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon", "imageUrls": ["https://images.wsj.net/im-407644/social"], "lang": "en", "cityfalconScore": 35, "additionalData": {}, "source": {"name": "wsj.com", "brandName": "The Wall Street Journal", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/large.png"}}, "duplicatesCount": 7, "paywall": true, "registrationRequired": true, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "06c11ce7-d7da-4e86-b9f4-9ebab6b4785e", "publishTime": "2021-10-04T11:00:09.000Z", "title": "A bear and a bull debate the move in health care after Merck\u2019s Covid pill breakthrough", "description": "Health-care stocks ended last week divided. Market analysts are divided, too.", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://www.cnbc.com/2021/10/04/merck-rallies-on-covid-pill-news-traders-discuss-health-care-stocks.html?utm_campaign=cityfalcon&utm_content=Main&utm_medium=cityfalcon&utm_source=cityfalcon&utm_term=Autofeed#Echobox=1633345253", "imageUrls": ["https://image.cnbcfm.com/api/v1/image/103260375-RTX1Z3H6t.jpg?v=1633118286"], "lang": "en", "cityfalconScore": 35, "additionalData": {}, "source": {"name": "cnbc.com", "brandName": "CNBC", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1665829/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1665829/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1665829/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1665829/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1665829/large.png"}}, "duplicatesCount": 3, "paywall": false, "registrationRequired": false, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "5bf51457-f617-4185-9391-f886d6a579e3", "publishTime": "2021-10-04T00:00:00.000Z", "title": "Here\u2019s Why Merck Stock May Continue To Rise", "description": "The stock price of Merck surged 8% to levels of $81 on Friday, Oct 1, after the company announced that its Molnupiravir pill reduces the risk of hospitalization and death by 50% for patients with mild to moderate Covid-19. The data is so encouraging that Merck has now stopped new patient enrollments", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://www.forbes.com/sites/greatspeculations/2021/10/04/heres-why-merck-stock-may-continue-to-rise/?utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon", "imageUrls": ["https://thumbor.forbes.com/thumbor/fit-in/1200x0/filters%3Aformat%28jpg%29/https%3A%2F%2Fspecials-images.forbesimg.com%2Fimageserve%2F6100ce859414378f9a8a7bf3%2F0x0.jpg"], "lang": "en", "cityfalconScore": 35, "additionalData": {}, "source": {"name": "forbes.com", "brandName": "Forbes", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/5846/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/5846/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/5846/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/5846/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/5846/large.png"}}, "duplicatesCount": 3, "paywall": false, "registrationRequired": false, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "f50eb192-08d7-4aad-8fb4-b29f41e4caba", "publishTime": "2021-10-11T00:00:00.000Z", "title": "Merck Seeks U.S. Emergency Approval For Antiviral Covid Pill", "description": "A late-stage trial showed the pill, which Merck is developing with Miami-based Ridgeback Therapeutics, halves the chances of hospitalization or death in recently diagnosed patients at risk of severe illness.", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://www.forbes.com/sites/roberthart/2021/10/11/merck-seeks-us-emergency-approval-for-antiviral-covid-pill/?utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon&utm_term=Gordie", "imageUrls": ["https://thumbor.forbes.com/thumbor/fit-in/1200x0/filters%3Aformat%28jpg%29/https%3A%2F%2Fspecials-images.forbesimg.com%2Fimageserve%2F6164138b1f4d69a3040b4d79%2F0x0.jpg%3FcropX1%3D0%26cropX2%3D3000%26cropY1%3D299%26cropY2%3D1987"], "lang": "en", "cityfalconScore": 35, "additionalData": {}, "source": {"name": "forbes.com", "brandName": "Forbes", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/5846/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/5846/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/5846/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/5846/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/5846/large.png"}}, "duplicatesCount": 3, "paywall": false, "registrationRequired": false, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "7d84cf73-7de6-4c63-8f44-0f2f257e6175", "publishTime": "2021-10-01T17:41:36.000Z", "title": "Why Moderna's stock is falling after Merck's Covid pill announcement", "description": "Steve Weiss, Short Hills Capital managing partner, joins 'The Halftime Report' to discuss Moderna's stock, which he is heavily invested in. \"This is absolutely ridiculous,\" he tells Scott Wapner as he tries to understand why Moderna's stock is falling after Merck's announcement that they're looking for emergency authorization of a Covid antiviral drug.", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://www.cnbc.com/video/2021/10/01/why-modernas-stock-is-falling-after-mercks-covid-pill-announcement.html?__source=iosappshare%7Ccom.apple.UIKit.activity.PostToTwitter&utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon", "imageUrls": ["https://image.cnbcfm.com/api/v1/image/106951021-16331071721633107169-18989658019-1080pnbcnews.jpg?v=1633107171"], "lang": "en", "cityfalconScore": 35, "additionalData": {}, "source": {"name": "cnbc.com", "brandName": "CNBC", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1665829/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1665829/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1665829/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1665829/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1665829/large.png"}}, "duplicatesCount": 2, "paywall": false, "registrationRequired": false, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "0e5d2a36-964e-4e18-8613-cf396e2026e2", "publishTime": "2021-10-11T10:29:39.000Z", "title": "Coronavirus tally: Global cases of COVID-19 near 238 million as Merck sees FDA approval for antiviral", "description": "The global tally for the coronavirus-borne illness climbed above 237.9 million on Monday, while the death toll rose above 4.85 million, according to data...", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://www.marketwatch.com/story/coronavirus-tally-global-cases-of-covid-19-near-238-million-as-merck-sees-fda-approval-for-antiviral-2021-10-11?utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon", "imageUrls": ["https://s.wsj.net/public/resources/MWimages/MW-GP644_MicroS_ZG_20180906154215.jpg"], "lang": "en", "cityfalconScore": 35, "additionalData": {}, "source": {"name": "marketwatch.com", "brandName": "MarketWatch", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/large.png"}}, "duplicatesCount": 1, "paywall": false, "registrationRequired": false, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "fc12e5ab-1cfa-4782-bdca-2285963ece4c", "publishTime": "2021-10-01T10:01:27.000Z", "title": "Merck to seek emergency authorization for oral Covid treatment after \u2018compelling results\u2019 in trials", "description": "Merck and Ridgeback Biotherapeutics will seek emergency authorization for their drug, which they say could have \u201ca profound impact in controlling the pandemic.\u201d", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://www.cnbc.com/2021/10/01/merck-to-seek-emergency-authorization-for-oral-covid-19-treatment.html?utm_campaign=cityfalcon&utm_content=Main&utm_medium=cityfalcon&utm_source=cityfalcon&utm_term=Autofeed#Echobox=1633082750", "imageUrls": ["https://image.cnbcfm.com/api/v1/image/106932657-16298382222021-08-24t194502z_193006969_rc2sbp9g5ksj_rtrmadp_0_health-coronavirus-usa.jpeg?v=1633080841"], "lang": "en", "cityfalconScore": 34, "additionalData": {}, "source": {"name": "cnbc.com", "brandName": "CNBC", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1665829/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1665829/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1665829/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1665829/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1665829/large.png"}}, "duplicatesCount": 34, "paywall": false, "registrationRequired": false, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "8f27f472-f3d3-4338-b2f1-50d396f761b5", "publishTime": "2021-10-11T10:05:30.000Z", "title": "Merck asks FDA to authorize antiviral Covid pill for emergency use", "description": "The Covid-19 treatment \u2013 known as molnupiravir \u2013 could be available to Americans by late this year.", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://www.cnbc.com/2021/10/11/covid-pill-merck-asks-fda-to-authorize-antiviral-for-emergency-use.html?utm_campaign=cityfalcon&utm_content=Main&utm_medium=cityfalcon&utm_source=cityfalcon&utm_term=Autofeed#Echobox=1633946818", "imageUrls": ["https://image.cnbcfm.com/api/v1/image/106848512-1614787765983-merck.jpg?v=1614787788"], "lang": "en", "cityfalconScore": 34, "additionalData": {}, "source": {"name": "cnbc.com", "brandName": "CNBC", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1665829/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1665829/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1665829/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1665829/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1665829/large.png"}}, "duplicatesCount": 22, "paywall": false, "registrationRequired": false, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "4031a8c6-5408-43b0-abc5-7ba18e8a394e", "publishTime": "2021-09-30T22:03:24.000Z", "title": "Stocks struggle to kick off October, Merck jumps on promising Covid treatment", "description": "The market ended a tumultuous September as inflation fears, slowing growth and rising rates crept up.", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://www.cnbc.com/2021/09/30/stock-market-futures-open-to-close-news.html?__source=iosappshare%7Ccom.apple.UIKit.activity.CopyToPasteboard&fbclid=IwAR0Muc3QrzoifChPIrJ4aQgoi3rcs7ilc7sHDs3fNXGdYkWWrtL5CqXkxqI&utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon", "imageUrls": ["https://image.cnbcfm.com/api/v1/image/106944984-16322363172021-09-21t145441z_644209299_rc2eup944gck_rtrmadp_0_usa-stocks.jpeg?v=1632236385"], "lang": "en", "cityfalconScore": 34, "additionalData": {}, "source": {"name": "cnbc.com", "brandName": "CNBC", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1665829/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1665829/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1665829/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1665829/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1665829/large.png"}}, "duplicatesCount": 0, "paywall": false, "registrationRequired": false, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "a996293d-18f2-4f8e-9b8d-6fdb10826fbb", "publishTime": "2021-10-09T05:17:01.000Z", "title": "How Effective Is Molnupiravir? Fauci Says COVID-19 Vaccine Still Needed If Merck Drug Approved", "description": "A pair of Indian drugmakers on Friday requested permission to end late-stage trials of their generic versions of U.S.-based drugmaker Merck's drug molnupiravir.", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://www.ibtimes.com/how-effective-molnupiravir-fauci-says-covid-19-vaccine-still-needed-if-merck-drug-3308540?utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon&utm_term=Autofeed#Echobox=1633756774", "imageUrls": ["https://s1.ibtimes.com/sites/www.ibtimes.com/files/styles/full/public/2021/07/17/top-us-disease-expert-anthony-fauci-seen-speaking.jpg"], "lang": "en", "cityfalconScore": 34, "additionalData": {}, "source": {"name": "ibtimes.com", "brandName": "IBTimes", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/676/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/676/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/676/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/676/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/676/large.png"}}, "duplicatesCount": 0, "paywall": false, "registrationRequired": false, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "2b52fbe0-50a4-4527-b280-709c48f04402", "publishTime": "2021-10-01T16:46:56.000Z", "title": "Stocks making the biggest moves midday: Merck, Moderna, United Airlines and more", "description": "These are the stocks posting the largest moves in midday trading.", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://www.cnbc.com/2021/10/01/stocks-making-the-biggest-moves-midday-merck-moderna-and-more.html?utm_campaign=cityfalcon&utm_content=Main&utm_medium=cityfalcon&utm_source=cityfalcon&utm_term=Autofeed#Echobox=1633106948", "imageUrls": ["https://image.cnbcfm.com/api/v1/image/106950955-1633101917812SLVM-Photo-20211001-Press-6.jpg?v=1633102135"], "lang": "en", "cityfalconScore": 33, "additionalData": {}, "source": {"name": "cnbc.com", "brandName": "CNBC", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1665829/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1665829/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1665829/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1665829/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1665829/large.png"}}, "duplicatesCount": 24, "paywall": false, "registrationRequired": false, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "5168da50-9bbb-406b-bd03-d8be491a4be6", "publishTime": "2021-09-30T10:54:44.000Z", "title": "Merck to buy Acceleron for about $11.5 billion in rare-disease drugs push", "description": "Merck will buy drugmaker Acceleron Pharma for about $11.5 billion, the companies said on Thursday.", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://www.cnbc.com/2021/09/30/merck-to-buy-drugmaker-acceleron-for-about-11point5-billion.html?utm_campaign=cityfalcon&utm_content=Main&utm_medium=cityfalcon&utm_source=cityfalcon#Echobox=1632999753", "imageUrls": ["https://image.cnbcfm.com/api/v1/image/106848512-1614787765983-merck.jpg?v=1614787788"], "lang": "en", "cityfalconScore": 33, "additionalData": {}, "source": {"name": "cnbc.com", "brandName": "CNBC", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1665829/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1665829/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1665829/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1665829/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1665829/large.png"}}, "duplicatesCount": 6, "paywall": false, "registrationRequired": false, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "2aead253-ef8a-4132-bee4-66ffd5d4b140", "publishTime": "2021-09-21T17:14:00.000Z", "title": "Nektar Therapeutics Shares Rise 5% on Deal With Pfizer, Merck KGaA", "description": "By Chris Wack Nektar Therapeutics shares were up 5% to $17.10 after the company said it entered into a new oncology clinical collaboration with Merck KGaA...", "assetTags": ["Merck KGaA", "MRK FSE", "MRK DE"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://www.marketwatch.com/story/nektar-therapeutics-shares-rise-5-on-deal-with-pfizer-merck-kgaa-271632244455?reflink=mw_share_twitter&utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon", "imageUrls": ["https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png"], "lang": "en", "cityfalconScore": 33, "additionalData": {}, "source": {"name": "marketwatch.com", "brandName": "MarketWatch", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/large.png"}}, "duplicatesCount": 1, "paywall": false, "registrationRequired": false, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "a76753a0-e38d-4e28-bf0a-d5e76c65ef20", "publishTime": "2021-10-10T21:48:00.000Z", "title": "Opinion | Who Slowed Merck\u2019s Covid Remedy?", "description": "A \u2018whistleblower,\u2019 not Trump officials, delayed funding for molnupiravir.", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://www.wsj.com/articles/covid-remedy-antiviral-government-funding-merck-molnupiravir-11633897174?mod=e2tw&utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon", "imageUrls": ["https://images.wsj.net/im-414616/social"], "lang": "en", "cityfalconScore": 33, "additionalData": {}, "source": {"name": "wsj.com", "brandName": "The Wall Street Journal", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/large.png"}}, "duplicatesCount": 1, "paywall": true, "registrationRequired": true, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "6e7dffff-2061-41e5-8545-627d03f5e407", "publishTime": "2021-10-12T00:00:00.000Z", "title": "Merck Reportedly Plans To Double Production Of New Covid-Fighting Pill As Wealthy Countries Corner Scarce Supplies", "description": "The company says the pill can cut the risk of hospitalization or death in Covid-19 patients by half.", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://www.forbes.com/sites/roberthart/2021/10/12/merck-reportedly-plans-to-double-production-of-new-covid-fighting-pill-as-wealthy-countries-corner-scarce-supplies/?utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon&utm_term=Gordie", "imageUrls": ["https://thumbor.forbes.com/thumbor/fit-in/1200x0/filters%3Aformat%28jpg%29/https%3A%2F%2Fspecials-images.forbesimg.com%2Fimageserve%2F6164138b1f4d69a3040b4d79%2F0x0.jpg%3FcropX1%3D0%26cropX2%3D2999%26cropY1%3D447%26cropY2%3D2135"], "lang": "en", "cityfalconScore": 33, "additionalData": {}, "source": {"name": "forbes.com", "brandName": "Forbes", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/5846/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/5846/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/5846/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/5846/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/5846/large.png"}}, "duplicatesCount": 1, "paywall": false, "registrationRequired": false, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "7bb8632b-8e32-48a0-80f3-c686a61c6904", "publishTime": "2021-09-20T07:14:00.000Z", "title": "Merck KGaA to Invest More Than $3.5 Bln in Electronics Business", "description": "By Joshua Kirby Merck KGaA said Monday that it will invest in its electronics business over the coming years, as it looks to capitalize on global growth in...", "assetTags": ["Merck KGaA", "MRK FSE", "MRK DE"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://www.marketwatch.com/story/merck-kgaa-to-invest-more-than-3-5-bln-in-electronics-business-271632122086?mod=newsviewer_click&utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon", "imageUrls": ["https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png"], "lang": "en", "cityfalconScore": 33, "additionalData": {}, "source": {"name": "marketwatch.com", "brandName": "MarketWatch", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/large.png"}}, "duplicatesCount": 0, "paywall": false, "registrationRequired": false, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "e5e6a28d-2083-4890-a207-a5871f3be3d1", "publishTime": "2021-10-01T00:00:00.000Z", "title": "Moderna Crash Wipes Out $22 Billion In Value After Merck's Covid Pill Triggers Vaccine Stock Plunge", "description": "Moderna tanked 15% Friday, while Novavax and BioNtech sank as much as 18%.", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://www.forbes.com/sites/jonathanponciano/2021/10/01/moderna-crash-wipes-out-22-billion-in-value-after-mercks-covid-pill-triggers-vaccine-stock-plunge/?utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon", "imageUrls": ["https://thumbor.forbes.com/thumbor/fit-in/1200x0/filters%3Aformat%28jpg%29/https%3A%2F%2Fspecials-images.forbesimg.com%2Fimageserve%2F5fb28ca3d78ca241bff521b6%2F0x0.jpg"], "lang": "en", "cityfalconScore": 32, "additionalData": {}, "source": {"name": "forbes.com", "brandName": "Forbes", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/5846/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/5846/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/5846/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/5846/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/5846/large.png"}}, "duplicatesCount": 303, "paywall": false, "registrationRequired": false, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "8c61ecd3-2481-4b9c-8490-f84219423f3e", "publishTime": "2021-10-01T10:53:00.000Z", "title": "AMC, Bitcoin, Lordstown, Merck: What to Watch When the Stock Market Opens Today", "description": "AMC reduced its debt costs; Merck\u2019s Covid-19 pill performed well in a study.", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://www.wsj.com/articles/amc-bitcoin-lordstown-merck-what-to-watch-when-the-stock-market-opens-today-11633085635?mod=latest_headlines&utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon", "imageUrls": ["https://images.wsj.net/im-409716/social"], "lang": "en", "cityfalconScore": 32, "additionalData": {}, "source": {"name": "wsj.com", "brandName": "The Wall Street Journal", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/large.png"}}, "duplicatesCount": 29, "paywall": true, "registrationRequired": true, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "5c40c4a3-65e0-4e83-aed6-052f19bcdc21", "publishTime": "2021-10-04T10:50:00.000Z", "title": "Tesla, Merck, Moderna: What to Watch When the Stock Market Opens Today", "description": "Tesla reported record deliveries in the third quarter; Merck shares were extending gains from last week.", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://www.wsj.com/articles/tesla-merck-moderna-what-to-watch-when-the-stock-market-opens-today-11633344618?reflink=e2twmkts&utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon", "imageUrls": ["https://images.wsj.net/im-403216/social"], "lang": "en", "cityfalconScore": 32, "additionalData": {}, "source": {"name": "wsj.com", "brandName": "The Wall Street Journal", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/large.png"}}, "duplicatesCount": 17, "paywall": true, "registrationRequired": true, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "d0fcad23-4e2f-41d8-ba92-58a5f4550b11", "publishTime": "2021-10-11T14:42:00.000Z", "title": "Merck seeks authorization for what would be first pill to treat COVID-19, and AstraZeneca reports positive results for antibody treatment", "description": "The global tally of confirmed cases of the coronavirus-borne illness COVID-19 edged closer to 238 million on Monday, as Merck submitted an application to the...", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://www.marketwatch.com/story/merck-seeks-authorization-for-what-would-be-first-pill-to-treat-covid-19-and-astrazeneca-reports-positive-results-for-antibody-treatment-11633963392?siteid=bullytweet&utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon", "imageUrls": ["https://images.mktw.net/im-410159/social"], "lang": "en", "cityfalconScore": 32, "additionalData": {}, "source": {"name": "marketwatch.com", "brandName": "MarketWatch", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/large.png"}}, "duplicatesCount": 4, "paywall": false, "registrationRequired": false, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "258b8e61-3a85-4af7-9a8e-11e828f40b50", "publishTime": "2021-10-01T21:52:00.000Z", "title": "\u2018It\u2019s not a magic pill\u2019: What Merck\u2019s antiviral pill could mean for vaccine hesitancy", "description": "Merck and Ridgeback Therapeutics are seeking emergency approval 10 days after sharing initial results showing molnupiravir cuts the risk of death or...", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://www.marketwatch.com/story/what-mercks-antiviral-pill-could-mean-for-vaccine-hesitancy-its-not-a-magic-pill-11633125181?utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon", "imageUrls": ["https://images.mktw.net/im-410523/social"], "lang": "en", "cityfalconScore": 32, "additionalData": {}, "source": {"name": "marketwatch.com", "brandName": "MarketWatch", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/large.png"}}, "duplicatesCount": 0, "paywall": false, "registrationRequired": false, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "dab83f88-0c0d-4e61-aac5-45f1c059dc30", "publishTime": "2021-10-01T14:49:00.000Z", "title": "\u2018This is a profound game changer\u2019: Merck\u2019s antiviral pill cuts risk of COVID-19 hospitalization and death in half, data show", "description": "Former FDA head says Merck's oral pill could become a powerful tool in combating COVID in high-risk patients who are already symptomatic.", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://www.marketwatch.com/story/merck-cheers-health-experts-with-news-antiviral-cut-risk-of-hospitalization-and-death-by-half-in-trial-and-could-become-powerful-tool-in-combating-covid-19-11633099780?siteid=bullytweet&utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon", "imageUrls": ["https://images.mktw.net/im-407814/social"], "lang": "en", "cityfalconScore": 31, "additionalData": {}, "source": {"name": "marketwatch.com", "brandName": "MarketWatch", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/large.png"}}, "duplicatesCount": 4, "paywall": false, "registrationRequired": false, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "c83a4acf-6a0a-4435-ab6c-bbf608503a56", "publishTime": "2021-10-01T20:09:25.000Z", "title": "Dow surges nearly 500 points as Merck's experimental COVID drug delivers dose of optimism but stocks register weekly losses", "description": "U.S. stock indexes closed solidly higher Friday, with some of the upbeat mood on Wall Street to start October and the fourth quarter being attributed to an...", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://www.marketwatch.com/story/dow-surges-nearly-500-points-as-mercks-experimental-covid-drug-delivers-dose-of-optimism-but-stocks-register-weekly-losses-2021-10-01?mod=mw_quote_news&utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon", "imageUrls": ["https://s.wsj.net/public/resources/MWimages/MW-GP644_MicroS_ZG_20180906154215.jpg"], "lang": "en", "cityfalconScore": 31, "additionalData": {}, "source": {"name": "marketwatch.com", "brandName": "MarketWatch", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/large.png"}}, "duplicatesCount": 4, "paywall": false, "registrationRequired": false, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "99b51a64-2f96-408a-a6db-9626567242ff", "publishTime": "2021-09-30T12:35:00.000Z", "title": "Merck to Buy Acceleron Pharma for $11.5 Billion", "description": "The pharmaceutical giant enhances its rare-disease business with a bet on treatments for respiratory and blood diseases.", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://www.wsj.com/articles/merck-to-buy-acceleron-pharma-for-11-5-billion-11633005328?utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon", "imageUrls": ["https://images.wsj.net/im-409273/social"], "lang": "en", "cityfalconScore": 28, "additionalData": {}, "source": {"name": "wsj.com", "brandName": "The Wall Street Journal", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1661160/large.png"}}, "duplicatesCount": 11, "paywall": true, "registrationRequired": true, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "eb6a616b-e87e-4eed-9787-94b66f03ea4b", "publishTime": "2021-10-05T00:00:00.000Z", "title": "Will Regeneron Stock See Lower Levels After Merck\u2019s Positive Data?", "description": "The stock price of \u200bRegeneron has seen a 16% fall over the last twenty-one trading days, while it is down 6% over the last year. The volatility in REGN stock is being driven by the developments for REGEN-COV, its Covid-19 antibody cocktail. REGN stock plunged 6% in Friday (Oct 1) trade after Merck..", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://www.forbes.com/sites/greatspeculations/2021/10/05/will-regeneron-stock-see-lower-levels-after-mercks-positive-data/?utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon", "imageUrls": ["https://thumbor.forbes.com/thumbor/fit-in/1200x0/filters%3Aformat%28jpg%29/https%3A%2F%2Fspecials-images.forbesimg.com%2Fimageserve%2F607e8ae6634032ae9a5f7edb%2F0x0.jpg"], "lang": "en", "cityfalconScore": 26, "additionalData": {}, "source": {"name": "forbes.com", "brandName": "Forbes", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/5846/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/5846/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/5846/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/5846/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/5846/large.png"}}, "duplicatesCount": 1, "paywall": false, "registrationRequired": false, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "d2422fcc-6596-4997-be55-9133cd272968", "publishTime": "2021-09-22T00:00:00.000Z", "title": "Should You Buy Merck Stock At $72?", "description": "The stock price of \u200bMerck reached its all-time high of around $82 in Sep 2020. It has since hovered in the range of $70-80 for the better part of the last year, and it currently trades at levels of around $72. We believe that MRK stock is undervalued at its current levels, and investors can use...", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://www.forbes.com/sites/greatspeculations/2021/09/22/should-you-buy-merck-stock-at-72/?utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon", "imageUrls": ["https://thumbor.forbes.com/thumbor/fit-in/1200x0/filters%3Aformat%28jpg%29/https%3A%2F%2Fspecials-images.forbesimg.com%2Fimageserve%2F6100ce859414378f9a8a7bf3%2F0x0.jpg"], "lang": "en", "cityfalconScore": 24, "additionalData": {}, "source": {"name": "forbes.com", "brandName": "Forbes", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/5846/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/5846/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/5846/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/5846/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/5846/large.png"}}, "duplicatesCount": 1, "paywall": false, "registrationRequired": false, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "16017bd2-33d8-4e69-9fc0-9c6a263c7262", "publishTime": "2021-09-30T11:46:45.000Z", "title": "Merck CEO Davis provides update on highly anticipated Covid-19 pill", "description": "Merck CEO Rob Davis joins CNBC's \"Squawk Box\" and Meg Tirrell to provide an update on the company's highly anticipated Covid-19 pill molnupiravir, which is in late-stage testing.", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://www.cnbc.com/video/2021/09/30/merck-ceo-davis-provides-update-on-highly-anticipated-covid-19-pill.html?__source=iosappshare%7Ccom.apple.UIKit.activity.PostToTwitter&utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon", "imageUrls": ["https://image.cnbcfm.com/api/v1/image/106950046-16330015281633001525-18968254992-1080pnbcnews.jpg?v=1633001527"], "lang": "en", "cityfalconScore": 24, "additionalData": {}, "source": {"name": "cnbc.com", "brandName": "CNBC", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1665829/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1665829/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1665829/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1665829/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1665829/large.png"}}, "duplicatesCount": 0, "paywall": false, "registrationRequired": false, "cityfalcon_permalink": "https://www.cityfalcon.com"}, {"uuid": "3148a48a-81a1-4006-a4e7-3d84cc00747f", "publishTime": "2021-10-12T04:01:11.995Z", "title": "Become an FT subscriber to read: Merck aims to double supply of Covid-19 antiviral pill on rising demand", "description": "News, analysis and comment from the Financial Times, the world\u02bcs leading global business publication", "assetTags": ["Merck & Co", "MRK NYSE", "MRK US"], "searchTags": ["MRK"], "category": "major_publication", "url": "https://www.ft.com/content/5ec9bdf5-58e8-4f0d-9b07-979668e8bbb8?utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon", "imageUrls": null, "lang": "en", "cityfalconScore": 23, "additionalData": {}, "source": {"name": "ft.com", "brandName": "Financial Times", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3460/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3460/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3460/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3460/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3460/large.png"}}, "duplicatesCount": 7, "paywall": true, "registrationRequired": true, "cityfalcon_permalink": "https://www.cityfalcon.com"}]